載入...
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
BACKGROUND: Sunitinib and pazopanib are the only two targeted therapies for the first-line treatment of locally advanced or metastatic renal cell carcinoma (mRCC) recommended by the United Kingdom’s National Institute for Health and Care Excellence. Pazopanib demonstrated non-inferior efficacy and a...
Na minha lista:
| 發表在: | PLoS One |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Public Library of Science
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5479501/ https://ncbi.nlm.nih.gov/pubmed/28636648 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0175920 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|